If you would like to explore the possibility of participating in a clinical trial at Guthrie, please call 1-800-836-0388.

As a Guthrie cancer patient you will have the unique opportunity to participate in one or more of some 100 clinical research trials that involve new treatments for many cancer types.

As a Guthrie patient you may have the unique opportunity to take part in clinical research trials for atrial fibrillation, congestive heart failure, lipid disorders, heart attack and many more cardiology disease states.

As a Guthrie patient you may have an opportunity to take part in clinical research trials for celiac disease, Crohn’s disease, ulcerative colitis, reflux disease, hepatitis and many more gastroenterology disease states.

Clinical trials study new ways to prevent, detect and treat disease. If you take part in research, you help advance new investigational medical therapies. 

Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Oncology - General
Sub-Investigator(s):
Sponsors: Internal
Details (Indentifier #): NCT05694338
Title: A Phase 2, Dose-finding, Randomized,
Double-blind, Placebo-controlled, Multicenter
Study to Evaluate the Safety and Efficacy of
Efavaleukin Alfa Induction Therapy in Subjects
with Moderately to Severely Active Ulcerative
Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Matthew Lincoln, DO
Sub-Investigator(s):
Sponsors: Amgen
Details (Indentifier #): 04987307
Title: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (OBERON)
Department: Pulmonary
Diagnosis: Lung - COPD
Principal Investigator: Boyd Taylor Hehn, MD
Sponsors: Astra Zeneca
Details (Indentifier #): 05166889
Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Gilead Sciences
Details (Indentifier #): NCT05633654
Title: A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT04457596
Title: A021806, A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: NCI
Details (Indentifier #): NCT04340141
Title: A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
Department: Oncology
Diagnosis: Genito-urinary - Renal
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT03793166
Title: A151216 ALCHEMIST, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT02194738
Title: A221805: Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
Department: Oncology
Diagnosis: Gastrointestinal - Colon-Rectal
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
Details (Indentifier #): NCT04137107
Title: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles as Early Goal Directed Therapy for COVID-19 Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS):
Department: Pulmonary
Diagnosis: Infectious Disease
Sponsors: Direct Biologics
Details (Indentifier #): NCT05354141
Showing 1-10 of 41 Results